Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupFRA:MX6A +1.80%86 Current Ratio is 1.14 as of Dec. 2025, which is 3% above its 10-year median of 1.11. GuruFocus rates FRA:MX6A with a GF Score™ of 86/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Grand Pharmaceutical Group ranks worse than 77.9% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Grand Pharmaceutical Group's current ratio for the quarter that ended in Dec. 2025 was 1.14.
Grand Pharmaceutical Group has a current ratio of 1.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Grand Pharmaceutical Group's Current Ratio or its related term are showing as below:
FRA:MX6A'
s Current Ratio Range Over the Past 10 Years
Min: 0.69 Med: 1.11 Max: 1.24
Current: 1.14
During the past 13 years, Grand Pharmaceutical Group's highest Current Ratio was 1.24. The lowest was 0.69. And the median was 1.11.
FRA:MX6A's Current Ratio is ranked worse than 77.9% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:MX6A: 1.14
Grand Pharmaceutical Group (FRA:MX6A) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Grand Pharmaceutical Group Current Ratio Related Terms
Grand Pharmaceutical Group Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (FRA:MX6A) has a Current Ratio of 1.14 as of Dec. 2025. This is near median its historical median of 1.11. Over the past decade, Grand Pharmaceutical Group's Current Ratio has ranged from 0.69 to 1.24. According to the industry distribution chart, Grand Pharmaceutical Group ranks #779 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 77.9%.
Is Grand Pharmaceutical Group's Current Ratio too high?
Grand Pharmaceutical Group's current Current Ratio of 1.14 is near median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 1.24. The Drug Manufacturers industry median Current Ratio is 2.00. Grand Pharmaceutical Group's value of 1.14 is 43% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #779 out of 1000 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #779 out of 1000 companies for Current Ratio. This places Grand Pharmaceutical Group in the lower half of its industry. The industry median Current Ratio is 2.00. Grand Pharmaceutical Group's value of 1.14 is 43% below this benchmark. Historically, Grand Pharmaceutical Group's own Current Ratio has ranged from 0.69 to 1.24 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 2.00, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Current Ratio of 1.14 is 43% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Current Ratio is 1.14, which is near median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.57 — trading 10.3% below its estimated fair value. The current Current Ratio is 1.14, which is near median its 10-year median of 1.11 and 43% below the Drug Manufacturers industry median of 2.00. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Current Ratio is 1.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.57 is trading 10.3% below its estimated GF Value™ of €0.63.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
Current Ratio: 1.14 (near median its 10-year median of 1.11)
GF Value™: €0.63 vs. price of €0.57 (10.3% below fair value)
Industry Position: 43% below the Drug Manufacturers median (#779 of 1000)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score
Get the complete analysis for FRA:MX6A
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
